All In Biotech

BLA 761116 · Stemline Therapeutics INC

Elzonris

Tagraxofusp-Erzs · Injection · CD123 Interaction; Cytotoxin

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jul 26, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Dec 21, 2018

Approved uses

2

Original approval plus efficacy supplements

Registered trials

23

0 Phase 3, 10 recruiting

FAERS reports

538

459 serious, 161 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CAPILLARY LEAK SYNDROME Capillary Leak Syndrome (CLS) which may be life-threatening or fatal, can occur in patients receiving ELZONRIS. Monitor for signs and symptoms of CLS and take actions as recommended [see Warnings and Precautions ( 5.1 )] . WARNING: CAPILLARY LEAK SYNDROME See full prescribing information for complete boxed warning. Capillary Leak Syndrome (CLS), which may be life-threatening or fatal if not properly managed, can occur in patients receiving ELZONRIS. ( 5.1 )

What it is approved for

From the label in effect Dec 9, 2024.

ELZONRIS is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older. ELZONRIS is a CD123-directed cytotoxin indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older ( 1 )

Mechanism: Tagraxofusp-erzs is a CD123-directed cytotoxin composed of recombinant human interleukin-3 (IL-3) and truncated diphtheria toxin (DT) fusion protein that inhibits protein synthesis and causes cell death in CD123-expressing cells. 12.2 Pharmacodynamics The exposure-response relationships and the time course of pharmacodynamic response for ELZONRIS have not been fully characterized. 12.6 Immunogenicity The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody)...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 27, 2022 Supplement 5 · Efficacy OrphanLetterLabel
  • Dec 21, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelReview
1 products under this application
  • ELZONRIS · TAGRAXOFUSP-ERZS 1000MCG · SOLUTION, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tagraxofusp" as an intervention, any sponsor and status, largest first.

All 23 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • capillary leak syndrome130
  • pyrexia47
  • off label use43
  • death41
  • disease progression38
  • thrombocytopenia35
  • blood albumin decreased29
  • drug ineffective28
  • weight increased28
  • tumour lysis syndrome27
  • hypoalbuminaemia25
  • acute kidney injury24

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201958
202060
202175
202272
202387
202469
202563
202654

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Elzonris (Tagraxofusp-Erzs) · HCPCS J9269

2024 spending

$15.0M

Beneficiaries

11

262 claims

Per beneficiary

$1,366,700

2024 ASP limit $329.44 per unit

View as table
YearSpending
2020$10,778,976
2021$7,755,186
2022$9,179,726
2023$7,534,546
2024$15,033,699

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 11 on PubMed

Sponsor: Stemline Therapeutics INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.